睿知中国医院研究地图
候选清单

正在招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  2. 研究中心康复大学青岛中心医院Qingdao Central Hospital青岛医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05623982,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with histologically confirmed non-Hodgkin's lymphoma;

    入选标准第 5 条

  3. Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as per CTCAE 5.0 criteria;

    入选标准第 9 条

    Female subjects of childbearing potential or male subjects with partners of childbearing potential must use highly effective contraception from 7 days before the first dose until 12 weeks after treatment discontinuation. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;

    入选标准第 11 条

    Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment;

    排除标准第 17 条

  4. ECOG performance status score ≤2;

    入选标准第 8 条

  5. Presence of measurable lesions during the screening period (lymph node lesions with any long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm);

    入选标准第 7 条

  6. History of other malignancies within 5 years prior to the first dose;

    排除标准第 5 条

    HBsAg-positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit of detection; HCV antibody-positive with HCV-RNA levels ≥ the lower limit of detection; HIV antibody-positive;

    排除标准第 6 条

  7. Pregnant or lactating women;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05623982,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The subject is capable of understanding the informed consent form, voluntarily participates, and signs the informed consent form;
  2. No gender restrictions;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Patients with histologically confirmed non-Hodgkin's lymphoma;
  6. Patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL);
  7. Presence of measurable lesions during the screening period (lymph node lesions with any long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm);
  8. ECOG performance status score ≤2;
  9. Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as per CTCAE 5.0 criteria;
  10. Organ function levels meet the requirements before the first dose;
  11. Female subjects of childbearing potential or male subjects with partners of childbearing potential must use highly effective contraception from 7 days before the first dose until 12 weeks after treatment discontinuation. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
  12. The subject has the ability and willingness to comply with the study protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

排除标准:Exclusion Criteria:

  1. Pulmonary diseases classified as ≥Grade 3 according to NCI-CTCAE v5.0; patients currently diagnosed with interstitial lung disease (ILD);
  2. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;
  3. Active tuberculosis;
  4. Patients with active autoimmune diseases;
  5. History of other malignancies within 5 years prior to the first dose;
  6. HBsAg-positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit of detection; HCV antibody-positive with HCV-RNA levels ≥ the lower limit of detection; HIV antibody-positive;
  7. Poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg);
  8. History of severe cardiovascular or cerebrovascular diseases;
  9. Patients with a history of hypersensitivity to recombinant humanized antibodies or any excipients of GNC-038;
  10. Pregnant or lactating women;
  11. Patients with central nervous system involvement;
  12. Major surgery within 28 days before the first dose of this study or planned major surgery during the study period;
  13. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  14. Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-038 treatment;
  15. Current use of immunosuppressive therapy;
  16. Radiotherapy within 4 weeks before initiating GNC-038 treatment;
  17. Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment;
  18. CAR-T therapy within 12 weeks before initiating GNC-038 treatment;
  19. Use of any other investigational drug in a clinical trial within 4 weeks or 5 half-lives before the first dose of this study;
  20. Any other condition deemed unsuitable for participation in this clinical trial by the investigator.

引自 ClinicalTrials.gov, NCT05623982, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05623982,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05623982